Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > KRAS


Brief Information

Name:V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
Target Synonym:KRAS,V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:25
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

The purity of Human KRAS (2-185,G12D), His Tag (Cat. No. KRS-H51H4) is more than 90% and the molecular weight of this protein is around 24-34 kDa verified by SEC-MALS.


GTPase-Glo test kras activity, the GTP is ≤95%, as measured under the described conditions (QC tested).

Synonym Name



KRAS (Kirsten rat sarcoma 2 viral oncogene homolog) gene is a proto-oncogene that encodes a small GTPase transductor protein called KRAS. KRAS is also known as Ki-Ras, c-K-ras andc-Ki-ras. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Plays an important role in the regulation of cell proliferation, promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner. RAS is one of the most frequently mutated oncogenes in human cancer but the frequency and distribution of RAS gene mutations are not uniform. In details, mutation of glycine 12 (G12) causes RAS activation by interfering with GAP binding and GAP-stimulated GTP hydrolysis. The reference shows the pathway may as a potential therapy targets.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CWG-71a (Cellworks Group) CWG-71a Clinical Cellworks Neoplasms Details
RNA tumor vaccine (First Affiliated Hospital Bengbu Medical College) Phase 1 Clinical First Affiliated Hospital Bengbu Medical College Solid tumours Details
ELI-002 Amph-CpG-7909; ELI-002; ELI-002 2P; VED-002 Phase 2 Clinical Elicio Therapeutics Solid tumours Details
AZD-4785 AZD-4785; IONISKRAS2.5Rx Ionis Pharmaceuticals Inc Details
mRNA-5671 mRNA-5671 Moderna Inc, Merck & Co Inc Details
Pooled mutant-KRAS peptide vaccine (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) Sidney Kimmel Comprehensive Cancer Center Details
mDC3/8-KRAS Vaccine (University of Pennsylvania) Phase 1 Clinical University Of Pennsylvania Carcinoma, Pancreatic Ductal Details
BI-1701963 BI-1701963 Phase 1 Clinical Forma Therapeutics Solid tumours; Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasm Metastasis Details
CWG-71b CWG71b; CWG-71-b; CWG-71b Clinical Cellworks Group Neoplasms Details
CWG-59r CWG-59r; CWG-59-r; CWG59r Clinical Cellworks Group Neoplasms Details
CWG-89 CWG-89 Clinical Cellworks Group Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message